In addition, we found that TP53/TP63 and MYCs integratively organized the expression of the up- and down-regulated genes that were responsive to cisplatin administration, respectively, revealing these proteins as pivotal factors in the MoAs of cisplatin’s anti-tumor activities. The gene discussed is TP63; the disease is neoplasm.